Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

IMMU-114

Known as: Anti-HLA-DR Monoclonal Antibody IMMU-114 
A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
HLA-DR is a member of the MHC class II antigen family expressed on hematologic and solid tumors. Antibodies directed against HLA… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
2015
2015
Introduction. HLA-DR is expressed in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and other B-cell… Expand
Is this relevant?
2012
2012
In contrast to the conventional immunosuppressive agents and nonselective T-cell-depleting antibodies, selective depletion of… Expand
  • figure 1
  • figure 3
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
BACKGROUND The effect of a humanized anti-human leukocyte antigen-DR monoclonal antibody, IMMU-114, on the allogeneic immune… Expand
Is this relevant?
2011
2011
A pilot study of anti-human leukocyte antigen (HLA)-DR monoclonal antibody (mAb) in dogs with lymphoma was undertaken to verify… Expand
Is this relevant?
2010
2010
A humanized IgG4 anti-HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
The short circulating half-life and side effects of IFNα affect its dosing schedule and efficacy. Fusion of IFNα to a tumor… Expand
Is this relevant?
2010
2010
Download short circulating half-life and side effects of IFNα affect its dosing schedule and efficacy. Fusion of IFNα mor… Expand
Is this relevant?
2006
2006
HLA-DR is under investigation as a target for monoclonal antibody (mAb) therapy of malignancies. Here we describe a humanized… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?